FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 under
t
he Securities Exchange Act of 1934
For the month of September 2024
ICON plc
(Translation of registrant's name into English)
333-08704
(Commission file number)
South County Business Park, Leopardstown, Dublin 18, Ireland
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F __ Form 40-F ______
X
___
Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes______ No___
X
___
Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes______ No___
X
___
-------------------------------------------------------------------------------
EXHIBIT LIST
Exhibit Description
99.1 ICON plc Press Release issued September 3, 2024 - ICON plc
to Present at the Baird 2024 Global Healthcare Conference
-------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ICON plc
/s/ Brendan Brennan
Date: September 3, 2024 Brendan Brennan
Chief Financial Officer
Exhibit 99.1
ICON plc to Present at the Baird 2024 Global Healthcare Conference
Dublin, Ireland, September 3, 2024
- ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and
clinical research organisation, today announced that Dr. Steve Cutler, CEO of
ICON plc, will present at the Baird 2024 Global Healthcare Conference on
Tuesday, September 10, 2024 at 3:45pm ET.
Any changes to this event and links to the live webcast will be posted on the
Investor section of our website under "Events".
About ICON plc
ICON plc is a world-leading healthcare intelligence and clinical research
organisation. From molecule to medicine, we advance clinical research
providing outsourced services to pharmaceutical, biotechnology, medical device
and government and public health organisations. We develop new innovations,
drive emerging therapies forward and improve patient lives. With headquarters
in Dublin, Ireland, ICON employed approximately 41,100 employees in 97
locations in 55 countries as at June 30, 2024. For further information about
ICON, visit: www.iconplc.com.
This press release contains forward-looking statements, including statements
about our financial guidance. These statements are based on management's
current expectations and information currently available, including current
economic and industry conditions. These statements are not guarantees of
future performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press release. The
forward-looking statements are subject to future events, risks, uncertainties
and other factors that could cause actual results to differ materially from
those projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the opening
of new offices and offering of new services, the integration of new business
mergers and acquisitions, as well as other economic and global market
conditions and other risks and uncertainties detailed from time to time in SEC
reports filed by ICON, all of which are difficult to predict and some of which
are beyond our control. For these reasons, you should not place undue reliance
on these forward-looking statements when making investment decisions. The word
"expected" and variations of such words and similar expressions are intended
to identify forward-looking statements. Forward-looking statements are only as
of the date they are made and we do not undertake any obligation to update
publicly any forward-looking statement, either as a result of new information,
future events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports filed
by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other
reports, which are available on the SEC's website at http://www.sec.gov.
Source: ICON plc
Contact: Kate Haven Vice President Investor Relations +1888 381 7923
ICON/ICLR-G
{graphic omitted}